How to optimise medicines management for people with Parkinson's disease in hospital.

Despite more than a century of investigation, syphilis vaccine development has long been hindered by the unusual outer membrane of Treponema pallidum subsp. pallidum (TPA) and the historical inability to propagate the spirochete in vitro. Early observations using the rabbit model established that protective, antibody-mediated immunity is achievable. The recent characterization of the repertoire of TPA outer membrane proteins (OMPs) defined the universe of potential targets for protective antibodies and provided a critical foundation for ongoing syphilis vaccine development. Built on a "learning from nature" approach, the mapping of antibody responses elicited during natural infection against OMPs allowed the identification and prioritization of extracellular loops as vaccine targets. Immunization of animals with protein scaffolds displaying these targets generates high titers of antibodies able to recognize surface-exposed regions of the spirochete. Recent advances in long-term in vitro cultivation and genetic manipulation of TPA have enabled the development of assays to directly evaluate the functional activity of extracellular loops - specific antibodies in promoting opsonophagocytosis, growth inhibition, impairment of motility, and outer membrane disruption. Next-generation platforms are being explored to enhance immunogenicity, simplify production, and facilitate scalable translation of these immunogens toward clinical evaluation. In parallel, researchers are uncovering the sequence variability in OMPs across circulating TPA strains to understand how mutations can affect antibody recognition and global vaccine efficacy. Collectively, these advances position the field to leverage structural, immunological, and microbiological insights to counter the stealth pathogen and, ultimately, achieve an effective syphilis vaccine.